Aeterna Zentaris first one fourth revenues increase to $7.

Aeterna Zentaris first one fourth revenues increase to $7.4 million Aeterna Zentaris Inc . First Quarter 2011 Highlights Agreement signed with Yakult Honsha Co. Ltd. for the development, manufacture and commercialization of perifosine, in Japan.5 million) upon achieving certain pre-established milestones, including regulatory and clinical events in Japan, as well as double-digit royalties on future net sales of perifosine in Japan. THE BUSINESS has agreed to supply perifosine, on a cost-plus-basis, to Yakult.Receipt of net sales royalty milestone payment of $2.5 million from Cowen Healthcare Royalty Partners, L.P.$1.5 million grant, payable over a three-year period as partial reimbursement of qualifying expenditures, awarded to the ongoing company by the German Ministry of Education and Research to build up, to the scientific stage up, cytotoxic conjugates of the proprietary cytotoxic compound disorazol Z and peptides targeting G-protein coupled receptors, like the luteinizing hormone-releasing hormone receptors.At-the-Market sales agreement signed to market common shares through ATM issuances on the NASDAQ for aggregate gross proceeds not to exceed $19.